← Leaderboards
John A Oates
Vanderbilt University
$7,158,915
Attributed
$7,158,915
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.6M · FY2005–17$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$23,002,546 · 23
By mechanism
P50$19,888,245 · 6
R21$1,117,674 · 3
R01$1,022,785 · 2
P01$525,644 · 1
R41$374,051 · 1
M01$74,147 · 10
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- L Jackson Roberts$17,065,377
- Annet Kirabo$7,301,987
- Michael Frederick Hill$2,072,921
- David Bruce Mount$5,845,408
- L. Jackson Roberts II$940,760
Others in their field
Top investigators on “Prostaglandins”
- John C S Breitner · Johns Hopkins University$40,522,800
- Joshua A Boyce · Brigham And Women'S Hospital$24,685,287
- Garret A Fitzgerald · University Of Pennsylvania$19,462,065
- Marc L Peters-Golden · University Of Michigan At Ann Arbor$15,891,247
- Lewis C Becker · Johns Hopkins University$15,884,277
- Kafait U Malik · University Of Tennessee Health Sci Ctr$14,980,136
Research focus
ProstaglandinsCellsThromboxanesProstaglandin-Endoperoxide SynthaseBaseEnzymesHuman SubjectThromboxane A2Lipid PeroxidationClinical ResearchProstaglandin Endoperoxide SynthasePharmacologyProtein IsoformsEventSeriesPeroxidasesCyclooxygenase 2PreventEnzyme InhibitorsRattusInhibitor/AntagonistPreventionMastocytosisProteins
Grant awards (48)
Prevention of genomic instability by a scavenger of bifunctional electrophiles$203,975
R21 · FY2017 · CA · contact PI
Prevention of COX-2 Derived DNA and Histone Modifications in Cancer$158,464
R21 · FY2016 · CA · contact PI
Prevention of genomic instability by a scavenger of bifunctional electrophiles$122,946
R21 · FY2016 · CA · contact PI
Prevention of genomic instability by a scavenger of bifunctional electrophiles$57,361
R21 · FY2016 · CA · contact PI
Prevention of COX-2 Derived DNA and Histone Modifications in Cancer$14,337
R21 · FY2016 · CA · contact PI
Prevention of COX-2 Derived DNA and Histone Modifications in Cancer$221,049
R21 · FY2015 · CA · contact PI
Development of Compounds for the Prevention and Treatment of Rhabdomyolysis$374,051
R41 · FY2014 · DK · contact PI
Inhibition of Lipid Peroxidation in Subarachnoid Hemorrage$525,644
P01 · FY2011 · GM · contact PI
SCCOR in Hemostatic and Thrombotic Diseases$3,392,221
P50 · FY2010 · HL · contact PI
THE PHARMACOLOGY OF ASPIRIN$441,093
P50 · FY2010 · HL · contact PI
Lipid Modification of Proteins by the PGH Synthases$341,503
R01 · FY2010 · GM · contact PI
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION$197,313
P50 · FY2010 · GM · contact PI
SCCOR in Hemostatic and Thrombotic Diseases$3,356,440
P50 · FY2009 · HL · contact PI
THE PHARMACOLOGY OF ASPIRIN$503,685
P50 · FY2009 · HL · contact PI
Lipid Modification of Proteins by the PGH Synthases$341,000
R01 · FY2009 · GM · contact PI
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION$254,136
P50 · FY2009 · GM · contact PI
SCCOR in Hemostatic and Thrombotic Diseases$3,236,448
P50 · FY2008 · HL · contact PI
Research Center for Pharmacology and Drug Toxicology$1,530,303
P50 · FY2008 · GM · contact PI
THE PHARMACOLOGY OF ASPIRIN$485,744
P50 · FY2008 · HL · contact PI
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION$382,344
P50 · FY2008 · GM · contact PI
LOSS OF EFFECT OF ASPIRIN$199
M01 · FY2008 · RR · contact PI
EICOSANOID BIOSYNTHESIS DEFICIENCY$176
M01 · FY2008 · RR · contact PI
SCCOR in Hemostatic and Thrombotic Diseases$3,174,938
P50 · FY2007 · HL · contact PI
THE PHARMACOLOGY OF ASPIRIN$466,467
P50 · FY2007 · HL · contact PI
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION$383,359
P50 · FY2007 · GM · contact PI
LOSS OF EFFECT OF ASPIRIN$4,227
M01 · FY2007 · RR · contact PI
EICOSANOID BIOSYNTHESIS DEFICIENCY$3,730
M01 · FY2007 · RR · contact PI
THE PHARMACOLOGY OF ASPIRIN$469,784
P50 · FY2006 · HL · contact PI
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION$234,830
P50 · FY2006 · GM · contact PI
Lipid-Modification of Proteins in Alzheimer's Disease$152,889
R21 · FY2006 · AG · contact PI
LOSS OF EFFECT OF ASPIRIN$31,042
M01 · FY2006 · RR · contact PI
Lipid-Modification of Proteins in Alzheimer's Disease$186,653
R21 · FY2005 · AG
EICOSANOID BIOSYNTHESIS DEFICIENCY$9,671
M01 · FY2005 · RR
LOSS OF EFFECT OF ASPIRIN$7,830
M01 · FY2005 · RR
PARTICIPATION OF CYCLOOXYGENASE-2 OVERPRODUCTION OF PROSTAGLANDIN D2 IN PATIENT$7,368
M01 · FY2005 · RR
Participation of Cyclooxygenase-2 Overproduction of Prostaglandin D2 in Patient$9,904
M01 · FY2004 · RR
PROSTANOID BIOSYNTHESIS IN SYSTEMIC MASTOCYTOSIS$113,250
R01 · FY2003 · GM
PROSTANOID BIOSYNTHESIS IN SYSTEMIC MASTOCYTOSIS$113,407
R01 · FY2002 · GM
Clinical Pharmacology of Acetaminophen and Salicylate$0
P50 · FY2002 · GM
CYCLOOXYGENASE 2 /PROSTAGLANDIN D2 IN MASTOCYTOSIS$0
M01 · FY2002 · RR
PROSTANOID BIOSYNTHESIS IN SYSTEMIC MASTOCYTOSIS$113,625
R01 · FY2001 · GM
CYCLOOXYGENASE 2 /PROSTAGLANDIN D2 IN MASTOCYTOSIS$0
M01 · FY2001 · RR
Clinical Pharmacology of Acetaminophen and Salicylate$0
P50 · FY2001 · GM
CYCLOOXYGENASE 2 /PROSTAGLANDIN D2 IN MASTOCYTOSIS$0
M01 · FY2001 · RR
CYCLOOXYGENASE 2 /PROSTAGLANDIN D2 IN MASTOCYTOSIS$0
M01 · FY2001 · RR
RESEARCH CENTER FOR PHARMACOLOGY AND DRUG TOXICOLOGY$1,153,281
P50 · FY2000 · GM
REGULATION AND MEDIATION OF THE IMMUNE RESPONSE BY EICOSANOIDS$225,859
P50 · FY2000 · GM
CYCLOOXYGENASE 2 /PROSTAGLANDIN D2 IN MASTOCYTOSIS$0
M01 · FY2000 · RR